Pharmaview Competitive Assessment

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser

Decision Resources Pharmaview Competitive Assessment

Pfizer Adds to Its Pain Franchise and Further Diversifies Its Business with Accretive Financial Deal for King

— A Pharmaview Competitive Assessment from Decision Resources

Decision Resources is offering an exclusive Pharmaview competitive assessment entitled Pfizer Adds to Its Pain Franchise and Further Diversifies Its Business with Accretive Financial Deal for King. This session is ONLY available to Pharmaview subscribers.

Please contact us to learn how you can become a Pharmaview subscriber and attend this event.

One year after the closing of the Wyeth mega-merger, Pfizer is back in the hunt for new acquisitions, with a surprising deal for the troubled King Pharmaceuticals. Although King is struggling through the generic erosion of its leading Skelaxin franchise, Pfizer has made a tender offer at a 40 percent premium ($14.25 a share), valuing the company at $3.3B (net of cash). Why is Pfizer willing to make this investment in King, when its own business is on the verge of the biggest patent expiration in the industry’s history? What does Pfizer expect to gain from King’s business and will it help them manage through the upcoming Lipitor patent expiration?

Decision Resources’ Pharmaview Analyst Michael Latwis breaks down what this combination means to the pain franchise and future growth outlook for Pfizer.

In this 20 minute presentation, Mr. Latwis will answer the following questions:

Why is Pfizer interested in King’s business, which has been in decline throughout 2010?
How will this deal impact Pfizer’s pain franchise? What are the major opportunities and risks in King’s portfolio and pipeline?
What impact will the addition of King have on Pfizer’s ability to manage through the Lipitor patent expiration?
How does King’s business fit into Pfizer’s overall corporate strategy?
How does this deal help position Pfizer’s business for future growth?

Mr. Latwis will conduct a live Q & A session after the presentation.

Registration

Pfizer Adds to Its Pain Franchise and Further Diversifies Its Business with Accretive Financial Deal for King

October 22, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can become a Pharmaview subscriber and attend this event, please contact us using the information below.

In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Webinar Details

Date & Time
Friday, October 22, 2010
10 a.m. ET, 4 p.m. CET

Presentation: 30 minutes

Q & A: 15 minutes

About the Speaker

Michael Latwis, M.B.A., is a corporate analyst for Decision Resources’ Pharmaview team, covering the major pharmaceutical and biotech companies in the U.S. market. The majority of Mr. Latwis’ background is in the financial services industry, with ten years of experience as an equity analyst and buy-side portfolio manager at the Wealth Management Division of Barclays Bank. He received an M.B.A. in finance from Pace University in New York City and an undergraduate degree from Rutgers College in New Jersey.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 8 New England Executive Park • Burlington, MA 01803

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.